Literature DB >> 27057075

An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits.

Pierre Delanaye1, Richard J Glassock2, Hans Pottel3, Andrew D Rule4.   

Abstract

Defining chronic kidney disease (CKD) is the subject of intense debate in the current nephrology literature. The debate concerns the threshold value of estimated glomerular filtration rate (eGFR) used to make the diagnosis of CKD. Current recommendations argue that a universal threshold of 60 mL/min/1.73m(2) should be used. This threshold has been defended by epidemiological studies showing that the risk of mortality or end-stage renal disease increases with an eGFR below 60 mL/min/1.73m(2). However, a universal threshold does not take into account the physiologic decline in GFR with ageing nor does it account for the risk of mortality and end-stage renal disease being trivial with isolated eGFR levels just below 60 mL/min/1.73m(2) in older subjects and significantly increased with eGFR levels just above 60 mL/min/1.73m(2) among younger patients. Overestimation of the CKD prevalence in the elderly (medicalisation of senescence) and underestimation of CKD (potentially from treatable primary nephrologic diseases) in younger patients is of primary concern. An age-calibrated definition of CKD has been proposed to distinguish age-related from disease-related changes in eGFR. For patients younger than 40 years, CKD is defined by eGFR below 75 mL/min/1.73m(2). For patients with ages between 40 and 65 years, CKD is defined by 60 mL/min/1.73m(2). For subjects older than 65 years without albuminuria or proteinuria, CKD is defined by eGFR below 45 mL/min/1.73m(2).

Entities:  

Year:  2016        PMID: 27057075      PMCID: PMC4810758     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  76 in total

Review 1.  Senile nephrosclerosis--does it explain the decline in glomerular filtration rate with aging?

Authors:  Andrew D Rule; Lynn D Cornell; Emilio D Poggio
Journal:  Nephron Physiol       Date:  2011-08-10

2.  Lifetime Risk of CKD: What Does It Really Mean?

Authors:  Pierre Delanaye; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 8.237

3.  Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation?

Authors:  Pierre Delanaye; Hans Pottel; Rossini Botev; Lesley A Inker; Andrew S Levey
Journal:  Nephrol Dial Transplant       Date:  2013-06       Impact factor: 5.992

4.  A stable definition of chronic kidney disease improves knowledge and patient care.

Authors:  Josef Coresh; Andrew S Levey; Adeera Levin; Paul Stevens
Journal:  BMJ       Date:  2013-09-18

5.  Interpretation of creatinine clearance.

Authors:  M M Elseviers; G A Verpooten; M E De Broe; G G De Backer
Journal:  Lancet       Date:  1987-02-21       Impact factor: 79.321

6.  Cystatin C versus creatinine in determining risk based on kidney function.

Authors:  Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

7.  Day-to-day variability in spot urine albumin-creatinine ratio.

Authors:  Chetana N Naresh; Andrew Hayen; Alexander Weening; Jonathan C Craig; Steven J Chadban
Journal:  Am J Kidney Dis       Date:  2013-08-16       Impact factor: 8.860

8.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

9.  Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Robert H Hopkins; Donna E Sweet; Melissa Starkey; Paul Shekelle
Journal:  Ann Intern Med       Date:  2013-12-17       Impact factor: 25.391

Review 10.  Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis.

Authors:  Bakhtawar K Mahmoodi; Kunihiro Matsushita; Mark Woodward; Peter J Blankestijn; Massimo Cirillo; Takayoshi Ohkubo; Peter Rossing; Mark J Sarnak; Bénédicte Stengel; Kazumasa Yamagishi; Kentaro Yamashita; Luxia Zhang; Josef Coresh; Paul E de Jong; Brad C Astor
Journal:  Lancet       Date:  2012-09-24       Impact factor: 79.321

View more
  33 in total

Review 1.  The conundrums of chronic kidney disease and aging.

Authors:  Richard J Glassock; Aleksandar Denic; Andrew D Rule
Journal:  J Nephrol       Date:  2016-11-25       Impact factor: 3.902

2.  Characteristics of outpatients referred for a first consultation with a nephrologist: impact of different guidelines.

Authors:  Céline Schulz; Ziyad Messikh; Pascal Reboul; Sylvain Cariou; Pedram Ahmadpoor; Emilie Pambrun; Camelia Prelipcean; Florian Garo; Julien Prouvot; Pierre Delanaye; Olivier Moranne
Journal:  J Nephrol       Date:  2022-01-14       Impact factor: 4.393

Review 3.  The global burden of chronic kidney disease: estimates, variability and pitfalls.

Authors:  Richard J Glassock; David G Warnock; Pierre Delanaye
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

4.  Longitudinal Changes in Kidney Function Estimated from Cystatin C and Its Association with Mortality in Elderly Women.

Authors:  Linnea Malmgren; Fiona E McGuigan; Anders Christensson; Kristina E Akesson
Journal:  Nephron       Date:  2020-05-11       Impact factor: 2.847

5.  Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

Authors:  Alessio Strazzulla; Giuseppe Coppolino; Concetta Di Fatta; Francesca Giancotti; Giuseppina D'Onofrio; Maria Concetta Postorino; Maria Mazzitelli; Selma Valerie Mammone; Innocenza Gentile; Laura Rivoli; Eleonora Palella; Tiziana Gravina; Chiara Costa; Vincenzo Pisani; Vincenzo De Maria; Giorgio Settimo Barreca; Nadia Marascio; Alfredo Focà; Giorgio Fuiano; Elio Gulletta; Carlo Torti
Journal:  World J Hepatol       Date:  2016-07-08

Review 6.  CKD: A Call for an Age-Adapted Definition.

Authors:  Pierre Delanaye; Kitty J Jager; Arend Bökenkamp; Anders Christensson; Laurence Dubourg; Bjørn Odvar Eriksen; François Gaillard; Giovanni Gambaro; Markus van der Giet; Richard J Glassock; Olafur S Indridason; Marco van Londen; Christophe Mariat; Toralf Melsom; Olivier Moranne; Gunnar Nordin; Runolfur Palsson; Hans Pottel; Andrew D Rule; Elke Schaeffner; Maarten W Taal; Christine White; Anders Grubb; Jan A J G van den Brand
Journal:  J Am Soc Nephrol       Date:  2019-09-10       Impact factor: 10.121

7.  Estimating the prevalence of definitive chronic kidney disease in the Japanese general population.

Authors:  Kei Nagai; Koichi Asahi; Kunitoshi Iseki; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2021-04-10       Impact factor: 2.801

8.  Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.

Authors:  Su Jin Jeong; Seung Eun Lee; Dong Hyun Shin; Ie Byung Park; Hui Seung Lee; Kyoung-Ah Kim
Journal:  BMC Nephrol       Date:  2021-05-14       Impact factor: 2.388

Review 9.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

10.  A long-term nationwide study on chronic kidney disease-related mortality in Italy: trends and associated comorbidity.

Authors:  Simone Navarra; Anna Solini; Marco Giorgio Baroni; Luisa Frova; Enrico Grande
Journal:  J Nephrol       Date:  2021-08-06       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.